Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX® (PREDICT)

Allergan

Status: Completed

Conditions: Migraine Disorders

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02502123

GMA-CAN-NEU-0336

Details and patient eligibility

About

This study will prospectively assess long term heath related quality of life in chronic migraine patients currently being treated with OnabotulinumtoxinA for injection (BOTOX®) as standard of care.

Enrollment: 215 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients with chronic migraine eligible to receive treatment with onabotulinumtoxinA (BOTOX®) as standard of care.

Exclusion criteria

• Diagnosis of hemiplegic migraine, basilar migraine, ophthalmoplegic migraine or migrainous infarction, chronic tension-type headache, hypnic headache, hemicrania continua or new daily persistent headache.
• Patient who is currently taking or planning on taking opioid-containing products, barbiturates or combination for acute headache or pain condition.
• Treatment with any other botulinum toxin product for any condition within 3 months of the screening visit.
• Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other significant disease that might interfere with neuromuscular function.

Trial design

215 participants in 1 patient group

OnabotulinumtoxinA (BOTOX®)

Description:

Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.

Treatment:

Other: No Intervention